



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C07D 451/06, G01N 33/53 G01N 33/543, 33/541 C07D 451/12</p>		A1	<p>(11) International Publication Number: WO 93/12111 (43) International Publication Date: 24 June 1993 (24.06.93)</p>
<p>(21) International Application Number: PCT/US92/10857 (22) International Filing Date: 16 December 1992 (16.12.92)</p> <p>(30) Priority data: 808,515 16 December 1991 (16.12.91) US</p> <p>(71) Applicant: BIOSITE DIAGNOSTICS INCORPORATED [US/US]; 11303 Roselle Street, Suite D, San Diego, CA 92121 (US).</p> <p>(72) Inventor: BUECHLER, Kenneth, Francis ; 12523 Manifester Place, San Diego, CA 92130 (US).</p> <p>(74) Agents: CONSALVI, Mary, S. et al.; Lyon & Lyon, 611 West 6th Street, 34th Floor, Los Angeles, CA 90017 (US).</p>		<p>(81) Designated States: AU, CA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: NOVEL COCAINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE COCAINE DERIVATIVE CONJUGATES AND LABELS</p> <p>(57) Abstract</p> <p>Compounds are provided for the preparation of reagents, including labels which can be used in immunoassays of cocaine and cocaine metabolites. The compounds are derivatives of cocaine which are conjugated to antigenic proteins or polypeptides for the formation of antibodies for use in immunoassays. The compounds also may be conjugated to labels for use in immunoassays.</p>			



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 451/06, G01N 33/53 G01N 33/543, 33/541 C07D 451/12	A1	(11) International Publication Number: WO 93/12111 (43) International Publication Date: 24 June 1993 (24.06.93)		
(21) International Application Number: PCT/US92/10857 (22) International Filing Date: 16 December 1992 (16.12.92)		(81) Designated States: AU, CA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).		
(30) Priority data: 808,515 16 December 1991 (16.12.91) US		Published <i>With international search report.</i>		
(71) Applicant: BIOSITE DIAGNOSTICS INCORPORATED [US/US]; 11303 Roselle Street, Suite D, San Diego, CA 92121 (US).				
(72) Inventor: BUECHLER, Kenneth, Francis ; 12523 Manifesto Place, San Diego, CA 92130 (US).				
(74) Agents: CONSALVI, Mary, S. et al.; Lyon & Lyon, 611 West 6th Street, 34th Floor, Los Angeles, CA 90017 (US).				
(54) Title: NOVEL COCAINE DERIVATIVES AND PROTEIN AND POLYPEPTIDE COCAINE DERIVATIVE CONJUGATES AND LABELS				
(57) Abstract Compounds are provided for the preparation of reagents, including labels which can be used in immunoassays of cocaine and cocaine metabolites. The compounds are derivatives of cocaine which are conjugated to antigenic proteins or polypeptides for the formation of antibodies for use in immunoassays. The compounds also may be conjugated to labels for use in immunoassays.				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DESCRIPTIONNovel Cocaine Derivatives and Protein and
Polypeptide Cocaine Derivative Conjugates and LabelsField of the Invention

This invention is in the field of ligand receptor assays, including immunoassays, for the detection of selected analytes of cocaine in a fluid sample. More 5 particularly, this invention relates to methods for the synthesis of novel cocaine derivatives and protein and polypeptide cocaine derivative conjugates and labels for use in the preparation of antibodies to cocaine and cocaine metabolites and for use in the immunoassay 10 process.

Background of the Invention

Cocaine has been an abused drug for centuries. The ability to measure cocaine and cocaine metabolites, therefore, is vital to many medical and clinical ends, including 15 the treatment of cocaine addiction.

Cocaine is rapidly metabolized in the body to primarily benzoylecgonine and ecgonine. In cases where alcohol (ethanol) consumption is also associated with cocaine use, the cocaine is also metabolized to benzoylecgonine ethyl 20 ester and related aryl hydroxy metabolites (see, e.g., J. Anal. Toxicol. 8:38-42 (1984) and J. Anal. Toxicol. 3:59-63 (1979)). The benzoylecgonine ethyl ester and related metabolites have been identified to be more potent than cocaine and related metabolites and are believed to 25 be responsible for deaths associated with simultaneous alcohol and cocaine use. Accordingly, there is a medical need for antibodies and diagnostics to rapidly detect benzoylecgonine ethyl ester and related metabolites.

The preparation of antibodies to cocaine and cocaine 30 metabolites requires that a cocaine derivative be synthesized so that attachment to an antigenic polypeptide or

protein is possible. In addition, the cocaine derivative is attached to various polypeptides, proteins or labels for use in screening antibodies and in the immunoassay process. The cocaine derivative should mimic the structure of the cocaine metabolite sought to be measured. Therefore, the selection and synthesis of the types of cocaine derivatives for attachment to proteins, polypeptides or labels is critical.

In addition, the cocaine derivatives need to be stable to hydrolysis which might occur in an aqueous solution.

Summary of the Invention

The present invention is directed to novel cocaine derivatives which are synthesized for attachment to antigens (proteins or polypeptides) for the preparation of antibodies to cocaine and cocaine metabolites. The resulting novel antigens may be used for the production of antibodies using standard methods. Once generated, the antibodies and the novel derivatives may be used in the immunoassay process.

Definitions


As used in the specification and claims, "receptor" shall mean a protein or polypeptide molecule capable of binding a ligand, typically an antibody. "Ligand" shall mean the binding partner to the receptor. "Label" shall mean the ligand derivative covalently coupled to a dye or a means capable of generating a signal in an immunoassay process. As used in the specification and claims, the following use of-a parenthesis with a substituted benzene ring  shall indicate that the substitution

following the benzene ring may be at any of the following ortho, meta or para positions.



Detailed Description of the Preferred Embodiments

Novel compounds are described which are used in the generation of antibodies and, in the immunoassay process generally. The compounds are derivatives of cocaine and 5 cocaine metabolites, primarily derivatives of benzoylecgonine. The benzoyl moiety of benzoylecgonine ultimately is modified to provide a chemical arm for attachment to proteins or polypeptides. The design of the synthesis of the 10 chemical arm is constructed such that the benzoylecgonine derivative is displaced from the protein or polypeptide domain or label to allow the derivative to present itself to the binding domain of receptors.




In general, the compounds of this invention have the following formula:



15 wherein:




20



where A is an aliphatic linking group of from 1-10 carbons and 0-5 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained.

In addition, the general form of protein or poly-peptide molecules or labels derivatized with the cocaine derivatives are:






wherein:

R = -H, -CH₃

R' = -OH, -OCH₃, -OCH₂CH₃, -NHCH₃, -NHCH₂CH₃, -SCH₃,


10 -SCH₂CH₃




15

where A is an aliphatic linking group of from 1-10 carbons and 0-5 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained; and

where B is either of the following:



or




where Z is an aliphatic linking group of from 1-30 carbons and 10 heterocarbons and may be branched or straight chained; and

where P = an antigenic protein or polypeptide or a

5 protein, polypeptide or a label; and

where x = at least one and not greater than 100.

Preferred compounds of this invention will have the following formula:



wherein:

10 R = -H, -CH₃

R' = -OH, -OCH₃, -OCH₂CH₃, -NHCH₃, -NHCH₂CH₃,

R'' = -CH₂--NHCOASCOCH₃, -CH₂--NHASCOCH₃,

-CH₂--OASCOCH₃, -CH₂--OASH,

-CH₂--NHCOASH, -CH₂--NHASH,


15 -CO--NHCOASCOCH₃, -CO--NHASCOCH₃,

-CO--OASCOCH₃, -CO--OASH,

-CO--NHCOASH, -CO--NHASH,

where A is an aliphatic linking group of from 1-10 carbons and 0-5 heteroatoms (chalcogen and nitrogen) and 20 may be branched or straight chained.

In addition, the general form of the preferred protein or polypeptide molecules or labels derivatized with the cocaine derivatives are:



wherein:

R = -H, -CH₃

R' = -OH, -OCH₃, -OCH₂CH₃, -NHCH₃, -NHCH₂CH₃, -SCH₃,

-SCH₂CH₃

5 R''' = -CH₂--OASB-


-CH₂--NHCOASB-, -CH₂--NHASB-,

-CO--OASB-,

-CO--NHCOASB-, -CO--NHASB,

where A is an aliphatic linking group of from 1-5
10 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and
may be branched or straight chained; and


where B is either one of the following:



15 where Z is an aliphatic linking group of from
1-15 carbons and 0-5 heterocarbons and may be
branched or straight chained; and

where P = an antigenic protein or polypeptide or a protein, polypeptide or label; and where x = at least 1 and not greater than 50.

Particularly preferred (best mode) compounds of this invention have the following formula:



wherein:

R = -CH₃


R' = -OH, -NHCH₂CH₃,

R'' = -CO--NHCOASCOCH₃,

10 -CO--NHCOASH

where A is an aliphatic linking group of from 1-5 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained.

In addition, the general form of particularly preferred (best mode) protein or polypeptide molecules or labels derivatized with the cocaine derivatives are:




wherein:

R = -CH₃

R' = -OH, -NHCH₂CH₃,

20 R'' = -CO--NHCOASB-,

where A is an aliphatic linking group of from 1-5 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained; and
where B is either of the following:



where Z is an aliphatic linking group of from 1-10 carbons and 0-5 heterocarbons and may be branched or straight chained; and
where P = an antigenic protein or polypeptide or a
10 protein, polypeptide or label; and
where x = at least 1 and not greater than 30.

Of particular interest are compounds where the methyl ester of cocaine is changed to the methyl amide or the ethyl amide of benzoylecgonine. These compounds are preferred because they are less susceptible to hydrolysis in aqueous solutions than their ester analogues. Thus, the amide derivatives which mimic the configuration of the ester analogues can be used to prepare reagents for the preparation and screening of antibodies and for the immunoassay procedure. In addition to the amide moiety, the benzyl ether moiety which replaces the benzoyl ester also is less susceptible to hydrolysis in aqueous solutions. Thus, for example, the ethyl amide benzoyl ecgonine derivative is synthesized to prepare reagents for antibody preparation and screening and immunoassay for benzoylecgonine ethyl ester because the ethyl amide benzoylecgtonine moiety mimics the configuration and is less susceptible to hydrolysis than the benzoylecgonine ethyl ester. In addition, it is believed that the methyl ester of cocaine is spontaneously hydrolyzed in the blood of man and animals.
30 In the event that a highly specific antibody for cocaine

(benzoylecgonine methyl ester) is required then immunizing with an antigenic cocaine conjugate may not be successful because the methyl ester of the cocaine derivative would have a very short half life in the blood and thus anti-
5 bodies would actually be raised to the analogous benzoyl-ecgonine derivative. This problem is overcome in the present invention by the novel derivatives described herein; that is, the methyl amide benzoylecgonine derivative is used to mimic the cocaine molecule. The methyl
10 amide moiety is much less susceptible to hydrolysis than the methyl ester which assures greater success in the development of highly specific antibodies to cocaine.

Experimental Examples

Example 1

15 Synthesis of Acetylthiopropionic Acid

To a stirred solution of 3-mercaptopropionic acid (7 ml, 0.08 moles) and imidazole (5.4 g, 0.08 moles) in tetrahydrofuran (THF, 700 ml) was added dropwise over 15 minutes, under argon, a solution of 1-acetyl imidazole
20 (9.6 g, 0.087 moles) in THF (100 ml). The solution was allowed to stir a further 3 hours at room temperature after which time the THF was removed in vacuo. The residue was treated with ice-cold water (18 ml) and the resulting solution acidified with ice-cold concentrated
25 HCl (14.5 ml) to pH 1.5-2. The mixture was extracted with water (2x50 ml), dried over magnesium sulfate and evaporated. The residual crude yellow oily solid product (10.5 g) was recrystallized from chloroform-hexane to afford 4.8 g. (41% yield) acetylthiopropionic acid as a
30 white solid with a melting point of 44-45 C.

Example 2Synthesis of p-Acetylthiopropionamide Benzoic Acid

Acetylthiopropionic acid (0.5 g, 0.0034 moles) was dissolved in anhydrous THF (3 ml). Carbonyldiimidazole (0.55 g, 0.0034 moles) was added and the mixture was stirred at room temperature for 45 minutes. A solution of p-aminobenzoic acid (0.46 g, 0.0034 moles) in anhydrous THF (2 ml) was added dropwise to the activated imidazolide while stirring and the reaction mixture was stirred for 2.5 hours at room temperature. The solvent was removed in vacuo and THF/water (7:4 ratio, 11 ml) was added to the residue to form a milky solution. The solution was warmed on a 50 C water bath, water (300 ml) was added, and the mixture was stored at 4 C overnight. The crystals were filtered and washed extensively with water and the product was dried in a vacuum desiccator. The recovered product (1.3 g) exhibited a melting point of 222-224 C.

Example 3Synthesis of p-Acetylthiopropionamide Benzoylecgonine

To a stirred solution of p-acetylthiopropionamide benzoic acid (1.32 g, 0.0049 moles) in dry dimethylformamide (DMF, 8 ml) was added in one portion, under argon, carbonyldiimidazole (0.8 g, 0.0049 moles). The resulting solution was stirred at room temperature for 45 minutes and added in one portion, under argon, to a stirred solution of ecgonine hydrate (1.0 g, 0.0049 moles) in dry DMF (34 ml) containing 21% sodium ethoxide in ethanol (183 μ l, 0.0049 moles). The solution was heated at 60-65 C for 6 hours after which time the DMF was removed in vacuo. The residual oil was subjected to chromatography on a 5x25 cm VYDAC RP C18 column using a linear gradient of 30 mM potassium phosphate, pH 4.6, to methanol to afford 0.53 g (19% yield) of p-acetylthiopropionamide benzoylecgonine phosphate salt as a colorless foam.

Example 4Synthesis of p-Acetylthiopropionamide Benzoylecaonine Ethylamide

To a solution of p-acetylthiopropionamide benzoylecgonine (0.3 g, 0.00064 mol) and ethylamine hydrochloride (0.06 g, 0.0007 mol) in 2.9 ml dry dimethylformamide and pyridine (0.22 ml, 0.0027 mol) was added 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (0.134 g, 0.0007 mol). The flask was sealed and allowed 5 to sit at room temperature for 4 hr. Solvents were removed in vacuo and triturated with ethylether. The residue was dried in vacuo and the product was purified by 10 high performance liquid chromatography. The residue was dissolved in 0.75 ml 0.5 M potassium phosphate, 0.1 M potassium borate buffer, pH 7. Crude product in the 15 amount of 0.25 ml was injected onto a column (Vydac C18, 100 Å pore size, 10 µm particle size, 1 x 25 cm) and equilibrated in 0.02 M potassium phosphate, pH 4.6 at a flow rate of 2.0 ml/min. The product was eluted between 20 32 and 37 min with a gradient reaching 100% methanol in 50 min. The product of fractions from 4 chromatography runs was combined and solvents were removed in vacuo. The residue was triturated with methanol and filter. The 25 methanol was removed in vacuo and 88 mg of p-acetylthiopropionamide benzoylecgone ethylamide was recovered.

Preparation of Benzoylecaonine Analogue Attached to Keyhole Limpet Hemocyanin (KLH), Bovine Serum Albumin (BSA), and Alkaline Phosphatase (AP)

The attachment of benzoylecgone analogue to proteins is achieved by reacting the free thiol, generated by 30 hydrolysis of the p-acetylthiopropionamide benzoylecgone, to proteins which contain a reactive maleimide that is the result of derivatization of the protein with succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 35 (SMCC, Pierce Chemical Co.). The free thiol form of the benzoylecgone ligand analogue was generated by dissolv-

ing 30 mg of p-acetylthiopropionamide benzoylecggonine phosphate salt in 2.6 ml of 0.12 M potassium carbonate in 80% methanol and at 3 minutes into the reaction the thiol concentration was measured by DTNB to be 18.9mM. Potassium phosphate, potassium borate (0.5M/0.1 M), pH 7 was added to the thiol solution and the pH was adjusted to 7 with 1N hydrochloric acid. The thiol concentration was determined by the method of Ellman (Ellman, G.L., Arch. Biochem. Biophys., 82, 70 (1959)) to be 15 mM. The pH of the solution was adjusted to 7.0 with glacial acetic acid prior to coupling to proteins.

KLH (6 ml of 14mg/ml) was reacted with sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SULFO-SMCC by adding 15 mg of SULFO-SMCC and maintaining the pH between 7 and 7.5 with 1N potassium hydroxide over a period of one tour at room temperature while stirring. The protein was separated from the unreacted SULFO-SMCC by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, and 0.15 M sodium chloride, pH 7.0, and 24 ml of KLH-maleimide was collected at a concentration of 3.1 mg/ml. The free thiol containing benzoylecggonine analogue (1.7 ml of 14 mM) was added to 6 ml of 3.1 mg/ml KLH-maleimide and the solution was stirred for 4 hours at 4 C and then dialyzed against 3 volumes of one liter each of pyrogen-free phosphate-buffered saline, pH 7.4, prior to immunization.

BSA (3.5 ml of 20 mg/ml) was reacted with SMCC by adding a solution of 6.7 mg of SMCC in 0.3 ml acetonitrile and stirring the solution for one hour at room temperature while maintaining the pH between 7 and 7.5 with 1N potassium hydroxide. The protein was separated from unreacted materials by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, 0.15 M sodium chloride, pH 7.0. The free thiol form of the benzoylecggonine ligand analogue (0.17 ml of 14 mM) was added to the BSA-maleimide (2 ml at 8.2 mg/ml) and the solution was stirred for 4 hours at 4 C. The solution was used to coat

microtiter plates for the detection of antibodies that bind the benzoylecgonine ligand analogue by standard techniques.

AP (1.5 ml of 10.9 mg/ml) was reacted with SULFO-SMCC 5 by adding 3.1 mg of SULFO-SMCC to the solution and stirring at room temperature for one hour while maintaining the pH between 7.0 and 7.5 using 1 M potassium hydroxide. The protein was separated from the unreacted materials by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, 0.15 M sodium chloride, pH 7.0. The free thiol form of the benzoylecgonine ligand analogue (0.02 ml of 12 mM) was added to the AP-maleimide 10 (0.2 ml at 3.56 mg/ml) and the solution was stirred for 1.5 hours at 4 C. The protein was separated from unreacted materials by gel filtration chromatography in 0.1 M 15 potassium phosphate, 0.02 M potassium borate, 0.15 M sodium chloride, pH 7.0, and the benzoylecgonine ligand analogue conjugate was diluted for use in assays.

Preparation of Benzoylecgonine Ethylamide Analogue

20 Attached to Ferritin, Bovine Serum Albumin (BSA), and Alkaline Phosphatase (LAP)

The attachment of benzoylecgonine ethylamide analogue to proteins is achieved by reacting the free thiol, generated by hydrolysis of the p-acetylthiopropionamide benzoylecgonine ethylamide, to proteins which contain a reactive maleimide that is the result derivatization of the 25 protein with succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC, Pierce Chemical Co.). The free thiol form of the benzoylecgonine ligand analogue was generated by dissolving 8 mg of p-acetylthiopropionamide 30 benzoylecgonine ethylamide phosphate salt in 0.71 ml of 0.12 M potassium carbonate in 80% methanol and at 3 min into the reaction the thiol concentration was measured by DTNB to be 19.5 mM. Add 0.25 ml 0.5 M potassium phosphate/0.1 M potassium borate, pH 7, to the thiol solution 35

and adjust the pH to 7 with 1N hydrochloric acid. The thiol concentration was then 12.7 mM.

Ferritin (Horse spleen, Sigma Chemical Co.), (3 ml of 10 mg/ml) was reacted with sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SULFO-SMCC) by adding 5 mg of SULFO-SMCC and maintaining the pH between 7 and 15 mg of SULFO-SMCC and maintaining the pH between 7 and 7.5 with 1N potassium hydroxide over a period of one hour at room temperature while stirring. The protein was separated from the unreacted SULFO-SMCC by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, and 0.15 M sodium chloride, pH 7.0, and 9 ml of ferritin-maleimide was collected at a concentration of 10 3.1 mg/ml. The free thiol containing benzoyllecgonine ethylamide analogue (0.3 ml of 12.7 mM) was added to the 15 ferritin-maleimide and the solution was stirred for 4 hours at 4 C and then dialyzed against 3 volumes of one liter each of pyrogen-free phosphate-buffered saline, pH 7.4.

BSA (3.5 ml of 20 mg/ml) was reacted with SMCC by 20 adding a solution of 6.7 mg of SMCC in 0.3 ml acetonitrile and stirring the solution for one hour at room temperature while maintaining the pH between 7 and 7.5 with 1N potassium hydroxide. The protein was separated from unreacted materials by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, 0.15 M sodium 25 chloride, pH 7.0. The free thiol form of the benzoyllecgonine ethylamide analogue (0.2 ml of 12.7 mM) was added to the BSA-maleimide (2 ml at 8.2 mg/ml) and the solution was stirred for 4 hours at 4 C. The solution was used to coat 30 microtiter plates for the detection of antibodies that bind the benzoyllecgonine ethylamide analogue by standard techniques.

AP (1.5 ml of 10.9 mg/ml) was reacted with SULFO-SMCC by adding 3.1 mg of SULFO-SMCC to the solution and stirring 35 at room temperature for one hour while maintaining the pH between 7.0 and 7.5 using 1 M potassium hydroxide. The protein was separated from the unreacted materials by

gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, 0.15 M sodium chloride, pH 7.0. The free thiol form of the benzoylecgonine ethylamide analogue (0.02 ml of 12.7 mM) was added to the 5 AP-maleimide (0.2 ml at 3.56 mg/ml) and the solution was stirred for 1.5 hours at 4 C. The protein was separated from unreacted materials by gel filtration chromatography in 0.1 M potassium phosphate, 0.02 M potassium borate, 0.15 M sodium chloride, pH 7.0, and the benzoylecgonine 10 ethylamide analogue conjugate was diluted for use in assays.

Preparation of Latex-Immobilized Affinity-Purified Goat IgG Antibody Against the Fc Fragment of Mouse IgG

Affinity-purified goat-anti-mouse Fc (BiosPacific) 15 and polystyrene latex particles (sulfated, 1.07 μm) (Interfacial Dynamics) were incubated separately at 45 C for one hour, the antibody solution being buffered with 0.1 M 2-(N-morpholino) ethane sulfonic acid at pH 5.5. While vortexing the antibody solution, the suspension of 20 latex particles was added to the antibody solution such that the final concentration of antibody was 0.3 mg/ml and the solution contained 1% latex solids. The suspension was incubated for 2 hours at 45 C prior to centrifugation of the suspension to pellet the latex particles. The 25 latex pellet was resuspended in 1% bovine serum albumin in phosphate-buffered-saline (PBS) and incubated for one hour at room temperature. Following centrifugation to pellet the latex, the pellet was washed three times by resuspension in PBS and centrifugation. The final pellet was 30 resuspended in borate-buffered-saline, 0.1% sodium azide, pH 8.0, at a latex concentration of 1% solids. A 1% suspension of this latex preparation was capable of binding 40 $\mu\text{g}/\text{ml}$ of monoclonal antibody.


Production and Primary Selection of Monoclonal Antibodies

Immunization of Balb/c mice was performed according to the method of Liu, D., Pursell, R., and Levy, J. G., Clin Chem, 25, 527-538 (1987). Fusions of spleen cells with SP2/0-Ag14 myeloma cells, propagation of hybridomas, and cloning were performed by standard techniques. Selection of hybridomas for further cloning began with culture supernatant at the 96-well stage. A standard ELISA procedure was performed with benzoylecgonine attached to BSA adsorbed to the ELISA plate. Typically, a single fusion was plated out in twenty plates and approximately 10-20 wells per plate were positive by the ELISA assay. At this stage, a secondary selection could be performed if antibodies to the SMCC part of the linking arm were to be eliminated from further consideration. An ELISA assay using BSA derivatized with SMCC but not containing the benzoylecgonine derivative identified which of the positive clones that bound the BSA-benzoylecgonine ligand analogue were actually binding the SMCC-BSA. Depending on the particular objectives for the antibodies obtained, the antibodies specific for SMCC-BSA may be eliminated at this step.

The foregoing examples describe the invention in detail by way of illustration and example. It will be obvious to those skilled in the art that changes and modifications may be practiced within the scope of the following claims.

Claims:


1. Compounds of the formula:









wherein:

R = -H, -CH₃5 R' = -OH, -OCH₃, -OCH₂CH₃, -NHCH₃, -NHCH₂CH₃, -SCH₃,
-SCH₂CH₃R'' = -CH₂--NHCOASCOCH₃, -CH₂--NHASCOCH₃-CH₂--OASCOCH₃, -CH₂--OASH,-CH₂--NHCOASH, -CH₂--NHASH,10 -CO--NHCOASCOCH₃, -CO--NHASCOCH₃,-CO--OASCOCH₃, -CO--OASH,

-CO--NHCOASH, -CO--NHASH,


where A is an aliphatic linking group of from 1-10
carbons and 0-5 heteroatoms (chalcogen and nitrogen) and
15 may be branched or straight chained.2. An immunogenic protein or polypeptide molecule
or a protein or polypeptide molecule or a label deriva-
tized to a compound of the formula:

wherein:



where A is an aliphatic linking group of from 1-10
10 carbons and 0-5 heteroatoms (chalcogen and nitrogen) and
may be branched or straight chained; and

where B is either of the following:



15 where Z is an aliphatic linking group of from
1-30 carbons and 10 heterocarbons and may be
branched or straight chained; and


where P = an antigenic protein or polypeptide or a
protein, polypeptide or a label; and

where x = at least one and not greater than 100.







20 3. Antibodies prepared in response to an antigen comprising the compound immunogen of claim 1.

4. Antibodies prepared in response to an antigen comprising the derivatized immunogenic protein or polypeptide of claim 2.

5. Compounds of the formula:




wherein:



where A is an aliphatic linking group of from 1-10 carbons and 0-5 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained.

6. An immunogenic protein or polypeptide molecule
15 or a protein or polypeptide molecule or a label derivatized to a compound of the formula:



wherein:

$R = -H, -CH_3$

$R' = -OH, -OCH_3, -OCH_2CH_3, -NHCH_3, -NHCH_2CH_3, -SCH_3,$

$-SCH_2CH_3$

5 $R'' = -CH_2-\text{C}_6\text{H}_4-OASB-$


$-CH_2-\text{C}_6\text{H}_4-NHCOASB-, -CH_2-\text{C}_6\text{H}_4-NHASB-,$

$-CO-\text{C}_6\text{H}_4-OASB-,$

$-CO-\text{C}_6\text{H}_4-NHCOASB-, -CO-\text{C}_6\text{H}_4-NHASB,$

where A is an aliphatic linking group of from 1-5
10 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and
may be branched or straight chained; and

where B is either one of the following:




15 where Z is an aliphatic linking group of from
1-15 carbons and 0-5 heterocarbons and may be
branched or straight chained; and

where P = an antigenic protein or polypeptide or a
protein, polypeptide or label; and where x = at least 1
and not greater than 50.


20 7. Antibodies prepared in response to an antigen
comprising the compound immunogen of claim 5.

8. Antibodies prepared in response to an antigen comprising the derivatized immunogenic protein or polypeptide of claim 6.

9. Compounds of the formula:




5 wherein:




10 where A is an aliphatic linking group of from 1-5 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained.

10. An immunogenic protein or polypeptide molecule or a protein or polypeptide molecule or label derivatized
15 to a compound of the formula:




wherein:



22

where A is an aliphatic linking group of from 1-5 carbons and 0-3 heteroatoms (chalcogen and nitrogen) and may be branched or straight chained; and

where B is either of the following:



where Z is an aliphatic linking group of from 1-10 carbons and 0-5 heterocarbons and may be branched or straight chained; and

where P = an antigenic protein or polypeptide or a 10 protein, polypeptide or label; and

where x = at least 1 and not greater than 30.

11. Antibodies prepared in response to an antigen comprising the immunogenic compound of claim 9.

12. Antibodies prepared in response to an antigen 15 comprising the derivatized immunogenic protein or polypeptide of claim 10.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/10857

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 C07D451/06; G01N33/53; G01N33/543; G01N33/541
C07D451/12

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.C1. 5	C07D

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US,A,3 917 582 (SYVA CORPORATION) 4 November 1975 * complete document *	1-3
Y	US,A,4 045 420 (SYVA CORPORATION) 30 August 1977 * complete document *	1-3
Y	US,A,3 888 866 (SYVA CORPORATION) 10 June 1975 * complete document *	1-3
A	EP,A,0 459 387 (ABBOTT LABORATORIES) 4 December 1991 * page 8-9 *	1-3
P,Y	EP,A,0 467 078 (ABBOTT LABORATORIES) 22 January 1992 * example 1 *	1-3
		-/-

¹⁰ Special categories of cited documents :¹⁰^{"A"} document defining the general state of the art which is not considered to be of particular relevance^{"E"} earlier document but published on or after the international filing date^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^{"O"} document referring to an oral disclosure, use, exhibition or other means^{"P"} document published prior to the international filing date but later than the priority date claimed^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art^{"A"} document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

18 MARCH 1993

Date of Mailing of this International Search Report

25. 03. 93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

VAN BIJLEN H.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	EP,A,0 475 783 (BIOSITE DIAGNOSTICS INC.) 18 March 1992 * complete document * -----	1-4
P,X	WO,A,9 119 980 (DRUG SCREENING SYSTEMS, INC.) 26 December 1991 * page 16-17 * -----	1-3

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9210857
SA 68331

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 18/03/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-3917582	04-11-75	None		
US-A-4045420	30-08-77	US-A-	4123431	31-10-78
US-A-3888866	10-06-75	US-A-	4197237	08-04-80
EP-A-0459387	04-12-91	US-A- AU-A- CA-A- JP-A-	5155212 7727291 2043372 4235199	13-10-92 05-12-91 30-11-91 24-08-92
EP-A-0467078	22-01-92	CA-A- JP-A-	2047050 4232860	19-01-92 21-08-92
EP-A-0475783	18-03-92	US-A- AU-A- WO-A-	5143852 8536191 9205283	01-09-92 15-04-92 02-04-92
WO-A-9119980	26-12-91	AU-A-	8054291	07-01-92

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.